Thursday, June 18, 2026

Dance, Drama, and Dazzle in BabyMonster’s New Release!

BabyMonster released the full-performance version of "Forever"...

Korean Visitors Caught in Grand Canyon Graffiti Controversy!

Korean tourists have sparked controversy over defacing natural landmarks at the Grand Canyon National Park in Arizona, USA.

Russia Produces Propaganda Film On “North Korean Hero Stories”… “Narrativizing” Close North Korea-Russia Ties

Russia plans a propaganda film celebrating North Korean soldiers in the Kursk region, marking a deepening military alliance.

Tag: FDA

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

How ‘Sunlenkaju’ and ‘Sunlenkajeong’ Are Revolutionizing HIV-1 Therapy in 2026

FDA approves lenacapavir-based HIV treatments for patients with multidrug-resistant infections, enhancing options for difficult cases.

Samchundang Pharma CEO Claims FDA Recognition for Obesity Drug as Generic

Samchundang Pharma's CEO announces FDA recognition of oral semaglutide as a generic and withdraws $1.7 billion stock sale plan.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

April 2026: Major Regulatory Actions on Herbal Patches and Antibiotics in South Korea

The FDA suspended manufacturing and sales of several products for regulatory violations, including herbal patches and antibiotic tablets.

Exploring Cenobamate: How SK Biopharmaceuticals’ New Oral Suspension Benefits Adult Epilepsy Patients

SK Biopharmaceuticals submits NDA for Cenobamate oral suspension, enhancing treatment options for epilepsy patients with swallowing difficulties.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

Classys Unveils Aggressive Growth Strategy at AAD 2026: What’s Next for the U.S. Market?

Classys reveals its growth strategy for the U.S. market at AAD 2026, showcasing innovative products and emphasizing clinical efficacy.

HLB’s Liraglutide: A Game-Changer in Cholangiocarcinoma Treatment with FDA Priority Review

HLB's Elevar Therapeutics receives FDA Priority Review for lirafugratinib, a promising treatment for cholangiocarcinoma with a 47% response rate.

FDA’s Game-Changing Guidelines: What Asian Biotech Firms Must Know About Clinical Trial Efficiency

Clinical Trial Design is crucial for success in pharma; FDA's new rules could ease burdens but raise quality standards.

JLK Secures FDA Clearance for Stroke Analysis Solution… Advancing Clinical Workflow

JLK's "JLK-NCCT" receives FDA clearance for AI-based stroke analysis, enhancing early detection and triage in emergency settings.

2026년 바이오의약품 안전관리: 이상사례 과학적 분석의 모든 것

The FDA enhances adverse event evaluation and guides healthcare providers on self-injectable medications for patient safety.

Unlocking Cancer Treatment: ABL206 and ABL209’s Promising Non-Clinical Data Revealed at AACR

ABL Bio will present preclinical data for its ADCs ABL206 and ABL209 at AACR 2023, showcasing promising anti-cancer efficacy.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.